Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FATE Fate Therapeutics

Pre-Market Trading 11-15 04:28:49 EST

2.08

-0.09

-4.15%

High2.22	Low2.05	Vol1.80M
Open2.18	D1 Closing2.17	Amplitude7.83%
Mkt Cap236.90M	Tradable Cap205.48M	Total Shares113.89M
T/O3.77M	T/O Rate1.82%	Tradable Shares98.79M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"FATE","market":"US","secType":"STK","nameCN":"Fate Therapeutics","latestPrice":2.08,"timestamp":1731618000000,"preClose":2.17,"halted":0,"volume":1798443,"delay":0,"floatShares":98786864,"shares":113894333,"eps":-1.641185,"marketStatus":"Pre-Market Trading","change":-0.09,"latestTime":"11-15 04:28:49 EST","open":2.18,"high":2.22,"low":2.05,"amount":3771465.8976503997,"amplitude":0.078341,"askPrice":2.57,"askSize":100,"bidPrice":1.89,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.641185,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1731681000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1380600000000,"exchange":"NASDAQ","adjPreClose":2.08,"postHourTrading":{"tag":"盘后","latestPrice":2.08,"preClose":2.08,"latestTime":"19:57 EST","volume":25689,"amount":53432.96,"timestamp":1731632228828},"volumeRatio":1.2388392441225802,"impliedVol":4.3127,"impliedVolPercentile":0.996},"requestUrl":"/m/hq/s/FATE/tweets","defaultTab":"tweets","newsList":[{"id":"2483010874","title":"Fate Therapeutics Third Quarter 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2483010874","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483010874?lang=en_us&edition=fundamental","pubTime":"2024-11-14 19:43","pubTimestamp":1731584594,"startTime":"0","endTime":"0","summary":"NasdaqGM:FATE Earnings and Revenue History November 14th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 113%. Earnings per share  also surpassed analyst estimates by 3.4%.Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US.The company's shares are down 22% from a week ago.It is worth noting though that we have found 4 warning signs for Fate Therapeutics (1 can't be ignored!) that you need to take into consideration.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-therapeutics-third-quarter-2024-114314653.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FATE"],"gpt_icon":0},{"id":"2483584668","title":"Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Mereo Biopharma Group Plc (MREO) and Fate Therapeutics (FATE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483584668","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483584668?lang=en_us&edition=fundamental","pubTime":"2024-11-14 15:40","pubTimestamp":1731570052,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Belite Bio, Inc. ADR (BLTE – Research Report), Mer...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-belite-bio-inc-adr-blte-mereo-biopharma-group-plc-mreo-and-fate-therapeutics-fate?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-belite-bio-inc-adr-blte-mereo-biopharma-group-plc-mreo-and-fate-therapeutics-fate?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4007","HCSG","BK4137","BK4139","MREO","FATE","BLTE"],"gpt_icon":0},{"id":"2483984696","title":"Cautious Hold Rating for Fate Therapeutics Amidst Clinical Uncertainties and Financial Stability","url":"https://stock-news.laohu8.com/highlight/detail?id=2483984696","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483984696?lang=en_us&edition=fundamental","pubTime":"2024-11-14 15:40","pubTimestamp":1731570026,"startTime":"0","endTime":"0","summary":"Jack Allen, an analyst from Robert W. Baird, maintained the Hold rating on Fate Therapeutics (FATE – Research Report). The associated price target ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cautious-hold-rating-for-fate-therapeutics-amidst-clinical-uncertainties-and-financial-stability?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cautious-hold-rating-for-fate-therapeutics-amidst-clinical-uncertainties-and-financial-stability?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE"],"gpt_icon":0},{"id":"2483814386","title":"Fate Therapeutics’ Stock Volatility: Impact of Partnerships and Regulatory Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2483814386","media":"TIPRANKS","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483814386?lang=en_us&edition=fundamental","pubTime":"2024-11-14 14:02","pubTimestamp":1731564122,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc (FATE) has disclosed a new risk, in the Share Price & Shareholder Rights category. Fate Therapeutics Inc. faces significant v...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fate-therapeutics-stock-volatility-impact-of-partnerships-and-regulatory-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fate-therapeutics-stock-volatility-impact-of-partnerships-and-regulatory-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FATE"],"gpt_icon":0},{"id":"2483925118","title":"Fate Therapeutics Unveils Q3 2024 Financial Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2483925118","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483925118?lang=en_us&edition=fundamental","pubTime":"2024-11-14 11:57","pubTimestamp":1731556676,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc ( ($FATE) ) has released its Q3 earnings. Here is a breakdown of the information Fate Therapeutics Inc presented to its inves...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fate-therapeutics-unveils-q3-2024-financial-highlights?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fate-therapeutics-unveils-q3-2024-financial-highlights?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","BK4139"],"gpt_icon":0},{"id":"2483885821","title":"FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2483885821","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483885821?lang=en_us&edition=fundamental","pubTime":"2024-11-14 00:19","pubTimestamp":1731514740,"startTime":"0","endTime":"0","summary":"Fate Therapeutics FATE reported a loss of 40 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 42 cents. The company reported a loss of 46 cents per share in the year-ago period.The loss narrowed year over year due to higher collaboration revenues.The company earned collaboration revenues of $3.1 million, which beat the Zacks Consensus Estimate of $1 million. The figure also increased from $1.9 million reported in the year-ago quarter.Revenues were derived from preclinical development activities for a second collaboration candidate targeting an undisclosed solid tumor antigen under its collaboration with Ono.R&D expenses increased 1.1% to $34.6 million. G&A expenses increased 9.8% to $20.8 million.Cash, cash equivalents and investments as of Sept. 30, 2024, totaled $330.5 million.Shares of Fate have lost 36.3% year to date compared with the industry’s decline of 3.7%.FATE is focused on developing and manufacturing universal, off-the-s","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/j1FS0yeEY913fehDKxmAwA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/56d1b0639f9b169b5b1e773c99d1da8d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/j1FS0yeEY913fehDKxmAwA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/56d1b0639f9b169b5b1e773c99d1da8d"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-q3-earnings-beat-higher-161900939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FATE"],"gpt_icon":0},{"id":"2483600087","title":"Fate Therapeutics (FATE) Receives a Buy from Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2483600087","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483600087?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:19","pubTimestamp":1731503996,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Fate Therapeutics (FATE – Research Report) today and set a price target of $6.00. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/fate-therapeutics-fate-receives-a-buy-from-piper-sandler?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/fate-therapeutics-fate-receives-a-buy-from-piper-sandler?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","BK4139"],"gpt_icon":0},{"id":"2483659009","title":"Conservative Hold Rating for Fate Therapeutics Amid Early Pipeline Development and Unclear Competitive Edge","url":"https://stock-news.laohu8.com/highlight/detail?id=2483659009","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483659009?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:15","pubTimestamp":1731500151,"startTime":"0","endTime":"0","summary":"Fate Therapeutics (FATE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Etzer Darout f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/conservative-hold-rating-for-fate-therapeutics-amid-early-pipeline-development-and-unclear-competitive-edge?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/conservative-hold-rating-for-fate-therapeutics-amid-early-pipeline-development-and-unclear-competitive-edge?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE"],"gpt_icon":0},{"id":"2483742920","title":"Hold Rating Maintained for Fate Therapeutics Amid Early Development Stage and Financial Stability","url":"https://stock-news.laohu8.com/highlight/detail?id=2483742920","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483742920?lang=en_us&edition=fundamental","pubTime":"2024-11-13 18:24","pubTimestamp":1731493463,"startTime":"0","endTime":"0","summary":"Needham analyst Gil Blum has maintained their neutral stance on FATE stock, giving a Hold rating yesterday. Gil Blum has given his Hold rating due ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/hold-rating-maintained-for-fate-therapeutics-amid-early-development-stage-and-financial-stability?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/hold-rating-maintained-for-fate-therapeutics-amid-early-development-stage-and-financial-stability?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","SSI"],"gpt_icon":0},{"id":"2483071691","title":"Fate Therapeutics (FATE) Receives a Buy from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2483071691","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483071691?lang=en_us&edition=fundamental","pubTime":"2024-11-13 18:11","pubTimestamp":1731492672,"startTime":"0","endTime":"0","summary":"Barclays analyst Peter Lawson maintained a Buy rating on Fate Therapeutics (FATE – Research Report) today and set a price target of $10.00. The com...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/fate-therapeutics-fate-receives-a-buy-from-barclays-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/fate-therapeutics-fate-receives-a-buy-from-barclays-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FATE"],"gpt_icon":0},{"id":"2483504021","title":"U.S. RESEARCH ROUNDUP- AMN Healthcare Services, Chart Industries, Home Depot","url":"https://stock-news.laohu8.com/highlight/detail?id=2483504021","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483504021?lang=en_us&edition=fundamental","pubTime":"2024-11-13 15:03","pubTimestamp":1731481390,"startTime":"0","endTime":"0","summary":"Nov 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AMN Healthcare Services, Chart Industries and Home Depot, on Wedn","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COLD","LU0354030511.USD","AXSM","SHOP","BK4224","GTLS","PRME","AMN","IBP","PT","BBIO","BK4209","EWTX","ATLC","SATS","LU2065171402.SGD","LU1430594728.SGD","DAY","BLFS","LNW","NVAX","MOS","CAVA","LU1093756168.USD","HRTX","PTVE","BK4533","HD","LU0683600562.USD","CART","LU0820562030.AUD","HCAR","HSBC","IAC","ITOS","INDP","LEGN","NUVL","KZR","STIM","FATE","BHVN","BMY","PALI","DCOM","BK4539","EVCM","HON","ICUI","LINE"],"gpt_icon":1},{"id":"2483007016","title":"TD Cowen Sticks to Its Hold Rating for Fate Therapeutics (FATE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483007016","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483007016?lang=en_us&edition=fundamental","pubTime":"2024-11-13 10:45","pubTimestamp":1731465910,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Tara Bancroft from TD Cowen maintained a Hold rating on Fate Therapeutics (FATE – Research Report). The company’s s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-its-hold-rating-for-fate-therapeutics-fate?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-its-hold-rating-for-fate-therapeutics-fate?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","TD","COWN"],"gpt_icon":0},{"id":"2483062074","title":"Fate Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483062074","media":"reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483062074?lang=en_us&edition=fundamental","pubTime":"2024-11-13 07:31","pubTimestamp":1731454301,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc reports results for the quarter ended September 30 - Earnings SummaryFate Therapeutics Inc FATE.OQ reported a quarterly adjusted loss of 40 cents per share for the quarter ended ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nL8N3MJ3CI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE"],"gpt_icon":0},{"id":"2483098130","title":"Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483098130","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483098130?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:20","pubTimestamp":1731450006,"startTime":"0","endTime":"0","summary":"Fate Therapeutics  came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.46 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.76%. A quarter ago, it was expected that this clinical-stage biotech company that develops stem cell treatments would post a loss of $0.47 per share when it actually produced a loss of $0.33, delivering a surprise of 29.79%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Fate Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $3.07 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 249.32%. This compares to year-ago revenues of $1.94 million. The company has topped consensus revenue estimates four times over the last four quarters.Fate Therapeutics shares have lost about","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bHsRpCKrGzzbaGHEolBtWw--~B/aD02MTg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/023168c7ea091c342492be3899b280af","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bHsRpCKrGzzbaGHEolBtWw--~B/aD02MTg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/023168c7ea091c342492be3899b280af"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-therapeutics-fate-reports-q3-222006034.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FATE"],"gpt_icon":0},{"id":"2483068846","title":"Fate Therapeutics Q3 EPS $(0.40) Beats $(0.42) Estimate, Sales $3.07M Beat $1.32M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483068846","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483068846?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:39","pubTimestamp":1731447576,"startTime":"0","endTime":"0","summary":"Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.42) by 4.76 percent. This is a 13.04 percent increase over losses of $(0.46) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41920965/fate-therapeutics-q3-eps-0-40-beats-0-42-estimate-sales-3-07m-beat-1-32m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Fate Therapeutics Q3 EPS $(0.40) Beats $(0.42) Estimate, Sales $3.07M Beat $1.32M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE"],"gpt_icon":0},{"id":"2483068914","title":"Fate Therapeutics: Q3 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2483068914","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483068914?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:18","pubTimestamp":1731446313,"startTime":"0","endTime":"0","summary":"SAN DIEGO  — SAN DIEGO  — Fate Therapeutics Inc.  on Tuesday reported a loss of $47.7 million in its third quarter.On a per-share basis, the San Diego-based company said it had a loss of 40 cents.The results exceeded Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of 42 cents per share.The clinical-stage biotech company that develops stem cell treatments posted revenue of $3.1 million in the period, which also beat Street forecasts. Five analysts surveyed by Zacks expected $880,000.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-therapeutics-q3-earnings-snapshot-211833412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FATE"],"gpt_icon":0},{"id":"2482476094","title":"Fate Therapeutics Highlights Cancer-Selective, Her2-Targeting Profile of FT825 / Ono-8250 Car T-Cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2482476094","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482476094?lang=en_us&edition=fundamental","pubTime":"2024-11-10 02:30","pubTimestamp":1731177000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241109:nTUA7ZVXQT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FATE","BK4139"],"gpt_icon":0},{"id":"2482451088","title":"Fate Therapeutics Reports Positive Preclinical Data for Cancer Treatment Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2482451088","media":"MT Newswires Live","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482451088?lang=en_us&edition=fundamental","pubTime":"2024-11-09 05:53","pubTimestamp":1731102824,"startTime":"0","endTime":"0","summary":"Fate Therapeutics  said late Friday that preclinical data for its CAR T-cell candidate FT836 demonstrated the product's potential for durable anti-tumor activity without intervention.The data \"support the pan-cancer activity of MICA/B targeting, and indicate that our next-generation, iPSC-derived CAR T-cell platform has the potential to drive potent and durable anti-tumor activity without the need for administration of conditioning chemotherapy to deplete host immune cells,\" Bob Valamehr, head of research and development at Fate, said in a statement.Fate presented the data at the annual meeting of the Society of Immunotherapy of Cancer in Houston.FT836 combines multiple next-generation synthetic controls of CAR T-cell function including a novel \"Sword & Shield\" technology \"to address critical challenges that have limited CAR T cell safety and efficacy in treating solid tumors,\" the company said.Price: 2.47, Change: +0.05, Percent Change: +2.07","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4230","FATE","BK4139","BK4022","CAR"],"gpt_icon":0},{"id":"2482804455","title":"Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2482804455","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482804455?lang=en_us&edition=fundamental","pubTime":"2024-11-09 05:01","pubTimestamp":1731099660,"startTime":"0","endTime":"0","summary":"Multiplexed-engineered, iPSC-derived CAR T Cell Targets Proteins Expressed on Cancer Cells in Response to Cellular Stress and Malignant Transformation. Off-the-shelf Product Candidate Incorporates Novel Sword & Shield Technology Designed to Promote Functional Persistence without Conditioning Chemotherapy. FT836 Preclinical Data Shows Robust Antigen-mediated Expansion, Functional Persistence, and Durable Anti-tumor Activity in the Presence of Alloreactive T Cells. MICA/B targeting is emerging as a novel cancer-specific strategy to attack a wide range of solid tumors, however, proteolytic cleavage and shedding of MICA/B at the membrane-proximal α3 domain is a common mechanism of cancer resistance and escape from canonical NKG2D-mediated recognition. FT836 is designed to uniquely target and bind the α3 domain, which has been shown to stabilize MICA/B expression and induce robust cytolytic killing of tumor cells. At an oral presentation today at SITC entitled “Development of an Off-the-She","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/aNYnCivjpACGPp66c3GeEw--~B/aD0xNzA7dz0zMzQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7f213ae25843a1bfbaf8f0b96eb32e53","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/aNYnCivjpACGPp66c3GeEw--~B/aD0xNzA7dz0zMzQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7f213ae25843a1bfbaf8f0b96eb32e53"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-therapeutics-presents-pan-tumor-210100117.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SITC","CAR","WRD","BK4230","FATE","BK4080","BK4231","BK4022","BK4139"],"gpt_icon":0},{"id":"2481655438","title":"Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2481655438","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481655438?lang=en_us&edition=fundamental","pubTime":"2024-11-05 05:01","pubTimestamp":1730754060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241104:nTUA9WVSRY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","NDAQ","BK4588","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4112","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","FATE","LU2210149790.SGD","BK4139","LU2095319765.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fatetherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1843},{"period":"1month","weight":-0.318},{"period":"3month","weight":-0.3882},{"period":"6month","weight":-0.4667},{"period":"1year","weight":-0.1613},{"period":"ytd","weight":-0.4439}],"compareEarnings":[{"period":"1week","weight":-0.0038},{"period":"1month","weight":0.0234},{"period":"3month","weight":0.0704},{"period":"6month","weight":0.1207},{"period":"1year","weight":0.3195},{"period":"ytd","weight":0.2483}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.058546},{"month":2,"riseRate":0.636364,"avgChangeRate":0.08272},{"month":3,"riseRate":0.545455,"avgChangeRate":0.019657},{"month":4,"riseRate":0.545455,"avgChangeRate":-0.055265},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.016902},{"month":6,"riseRate":0.545455,"avgChangeRate":0.010259},{"month":7,"riseRate":0.454545,"avgChangeRate":0.056385},{"month":8,"riseRate":0.363636,"avgChangeRate":-0.021881},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.018445},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.106424},{"month":11,"riseRate":0.5,"avgChangeRate":0.073035},{"month":12,"riseRate":0.636364,"avgChangeRate":0.109378}],"exchange":"NASDAQ","name":"Fate Therapeutics","nameEN":"Fate Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Fate Therapeutics,FATE,Fate Therapeutics股票,Fate Therapeutics股票老虎,Fate Therapeutics股票老虎国际,Fate Therapeutics行情,Fate Therapeutics股票行情,Fate Therapeutics股价,Fate Therapeutics股市,Fate Therapeutics股票价格,Fate Therapeutics股票交易,Fate Therapeutics股票购买,Fate Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction